385 related articles for article (PubMed ID: 19357102)
1. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
[TBL] [Abstract][Full Text] [Related]
2. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
[TBL] [Abstract][Full Text] [Related]
3. Generic low-molecular-weight heparins: some practical considerations.
Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
[TBL] [Abstract][Full Text] [Related]
4. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
[TBL] [Abstract][Full Text] [Related]
5. The United States Food and Drugs Administration approves a generic enoxaparin.
Ofosu FA
Clin Appl Thromb Hemost; 2011 Feb; 17(1):5-8. PubMed ID: 21159709
[TBL] [Abstract][Full Text] [Related]
6. Development of generic low molecular weight heparins: a perspective.
Fareed J; Leong W; Hoppensteadt DA; Jeske WP; Walenga J; Bick RL
Hematol Oncol Clin North Am; 2005 Feb; 19(1):53-68, v-vi. PubMed ID: 15639108
[TBL] [Abstract][Full Text] [Related]
7. Overview on guidelines and recommendations for generic low-molecular-weight heparins.
Harenberg J
Thromb Res; 2011 Feb; 127 Suppl 3():S100-4. PubMed ID: 21262425
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
Walenga JM; Jackson CM; Kessler CM
Semin Thromb Hemost; 2011 Apr; 37(3):322-7. PubMed ID: 21455866
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
[TBL] [Abstract][Full Text] [Related]
10. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
[TBL] [Abstract][Full Text] [Related]
11. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
[TBL] [Abstract][Full Text] [Related]
12. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
Harenberg J
Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low-molecular-weight heparin: results of a study in healthy subjects with enoxaparin.
Kuczka K; Harder S; Picard-Willems B; Warnke A; Donath F; Bianchini P; Parma B; Blume H
J Clin Pharmacol; 2008 Oct; 48(10):1189-96. PubMed ID: 18716314
[TBL] [Abstract][Full Text] [Related]
14. Low molecular weight heparins copies: are they considered to be generics or biosimilars?
Minghetti P; Cilurzo F; Franzé S; Musazzi UM; Itri M
Drug Discov Today; 2013 Mar; 18(5-6):305-11. PubMed ID: 23153556
[TBL] [Abstract][Full Text] [Related]
15. Are the available low-molecular-weight heparin preparations the same?
Fareed J; Jeske W; Hoppensteadt D; Clarizio R; Walenga JM
Semin Thromb Hemost; 1996; 22 Suppl 1():77-91. PubMed ID: 8807734
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic equivalence of complex drugs.
Schellekens H; Klinger E; Mühlebach S; Brin JF; Storm G; Crommelin DJ
Regul Toxicol Pharmacol; 2011 Feb; 59(1):176-83. PubMed ID: 20951177
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of low molecular weight heparins in animal models.
Fareed J; Fu K; Yang LH; Hoppensteadt DA
Semin Thromb Hemost; 1999; 25 Suppl 3():51-5. PubMed ID: 10549716
[TBL] [Abstract][Full Text] [Related]
18. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
19. Generic and branded drugs for the treatment of people living with HIV/AIDS.
Bartlett JA; Muro EP
J Int Assoc Physicians AIDS Care (Chic); 2007 Mar; 6(1):15-23. PubMed ID: 17329500
[TBL] [Abstract][Full Text] [Related]
20. Past, present and future considerations on low molecular weight heparin differentiation: an epilogue.
Fareed J; Haas S; Sasahar A
Semin Thromb Hemost; 1999; 25 Suppl 3():145-7. PubMed ID: 10549730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]